BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.27 HKD | -2.31% |
|
-5.22% | -44.30% |
| May. 15 | Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China | MT |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 |
ETFs positioned on Brii Biosciences Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.177
CNY
Average target price
5.536
CNY
Spread / Average Target
+370.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.30% | 119M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- 2137 Stock
- Funds and ETFs Brii Biosciences Limited
